FloraWorks
FloraWorks is a pioneering cannabinoid research company focused on developing rare and novel cannabinoid-based therapeutics. Utilizing their AI-driven platform, Paragon™, they accelerate the discovery of cannabinoid applications, particularly in sleep aids like their flagship product, TruCBN™, which is clinically validated for improving sleep. With a commitment to innovation and collaboration, FloraWorks aims to transform the health landscape by providing effective alternatives to traditional medications, positioning themselves as leaders in the rapidly evolving cannabinoid market.
FloraWorks
FloraWorks is a pioneering cannabinoid research company focused on developing rare and novel cannabinoid-based therapeutics. Utilizing their AI-driven platform, Paragon™, they accelerate the discovery of cannabinoid applications, particularly in sleep aids like their flagship product, TruCBN™, which is clinically validated for improving sleep. With a commitment to innovation and collaboration, FloraWorks aims to transform the health landscape by providing effective alternatives to traditional medications, positioning themselves as leaders in the rapidly evolving cannabinoid market.
TL;DR
Sector: Biotechnology (cannabinoid ingredients & therapeutics)
Flagship product: TruCBN™ (purified CBN ingredient marketed for sleep)
Founded: 2019–2020 (sources list both 2019 and 2020)
Headquarters: Milwaukie, Oregon
Last known funding: Series A (Dec 15, 2022) — reported total funding ≈ $2.25M
Company Overview
Problem Domain
Discovery, production, and commercialization of hemp-derived minor cannabinoid ingredients for wellness and therapeutic use, with emphasis on sleep therapeutics.
Founded
2019
Industry
Biotechnology
Tech Stack
Funding Track Record
2250000
Platforms report a Series A; Dealroom summarizes a Series A of ~ $2.3M (Jun 2023) and Crunchbase lists a Series A on Dec 15, 2022. Reported investors include Arcview Group and Bonaventure Equity.
Investor Signal
“Arcview Group; Bonaventure Equity”